

THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT. THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.



An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients with Dementia



WP8: Impact Promotion, Dissemination, Exploitation and Business Planning

D8.3: Market Analysis and Exploitation Plan

Contractual Date of Delivery to the EC: 31 December 2022 (M18)

Actual Date of Delivery to the EC: 14 January 2023

Participant(s): ¹**EXYS**, ²Fraunhofer, ³SKB, ⁴WARWICK, ⁵UHCW, ⁶SESCAM, ⁷UCLM, ⁸CITST, ⁹SRDC, ¹⁰OCT

Author(s): ¹Angelo Consoli, ¹Jaouhar Ayadi, ¹Luca Gilardi, ⁶Pedro Abizanda Soler, ³Antje Steinhoff, ³Wolfgang Schmidt-Barzinski, ⁴Theo Arvanitis, ⁵Timothy Robbins, ⁸Oana Cramariuc, ⁹Gokce Banu Laleci Erturkmen, ⁹Mert Gencturk, ¹⁰Lionello Ferrazzini, ²Yehya Mohamad, ²Henrike Gappa, ⁴Sarah Lim Choi Keung, ⁴Theodoros Arvanitis, ⁵Timothy Robbins, ⁵Harpal Randeva, ⁵Ioannis Kyrou, ⁷Ana Magdalena Vargas Martinez, ⁸Oana Cramariuc, ¹⁰Lionello Ferrazzini

Type: (P-prototype, R-report, O-other, ORDP-Open Research Data Pilot, DEM-Demonstrator,

ET-Ethics): R

Dissemination level (PU-Public, CO-Confidential) : PU

Version: 3v0

Total number of pages: 61



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945169.

THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT. THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.

Executive Summary

This document reports on activities performed in Task 8.2, which include organizing and carrying out exploitation activities as well as identifying the commercial and market prospects that the CAREPATH project will present to the European health care and social care sectors. The first part of T8.2 activities are reported in the present deliverable D8.3, the results of which will guide the work to be done in the second part of T8.2, eventually leading to the deliverable D8.4 Reports on Exploitation Activities and Final Business Plan (M36).

D8.3 is the first release of Market Analysis and Exploitation Plan, due for M18, while a second release, refining and updating the first one, based on work and on the results obtained meanwhile, will be delivered by M24.

The objectives included in D8.3 are;

- Conducting a thorough market analysis and establishing the partners' competencies (Section 4 and Section 5.3).
- Identifying the exploitable assets of the project identified in WP8 Task 8.1 and carry out a Strength Weakness, Opportunities and Threats (SWOT) analysis for the specified alternative exploitation strategies.(Section 5.5.3).
- Creating exploitation plans with the involvement of all CAREPATH partners, using specific examples backed by realistic business cases (Section 5).

**THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL
DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT.
THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.**

Table of Contents

EXECUTIVE SUMMARY	2
1. INTRODUCTION	8
1.1 PROJECT INFORMATION.....	8
1.2 DOCUMENT SCOPE	8
1.3 DOCUMENT STRUCTURE.....	8
2. VISION AND OBJECTIVES OF CAREPATH PROJECT.....	9
2.1 SELF-MANAGEMENT OF MULTIMORBID ELDERLY PATIENTS WITH MCI AND MD	9
2.2 STRATEGIC OBJECTIVES OF CAREPATH.....	9
3. CARE LANDSCAPE OF MULTIMORBID PATIENTS WITH DEMENTIA	11
3.1 KEY FACTS, SYMPTOMS, AND TREATMENT.....	11
3.2 NATIONAL STRATEGIES IN EUROPE	12
3.2.1 Switzerland	12
3.2.2 Germany	13
3.2.3 United Kingdom	14
3.2.4 Spain.....	14
3.2.5 Romania.....	15
3.2.6 Turkey	16
3.3 ASPECTS TO BE SOLVED	17
3.3.1 Patients oriented aspects	17
3.3.2 Informal caregivers oriented aspects.....	18
3.3.3 Clinicians oriented aspects	19
3.3.4 Service provision through supported functionalities	19
4. MARKET ANALYSIS	20
4.1 PROFILE AND DIMENSION OF THE TARGET MARKET	20
4.1.1 Switzerland	20
4.1.1.1 Elderly market segment	20
4.1.1.2 CAREPATH related state of technology and development.....	22
4.1.1.3 Opportunities and barriers to introducing CAREPATH-like solution in health care	22
4.1.2 United Kingdom	23
4.1.2.1 Elderly market segment	23
4.1.2.2 CAREPATH related state of technology and development.....	23
4.1.2.3 Opportunities and barriers to introducing CAREPATH-like solution in health care	23
4.1.3 Spain.....	24
4.1.3.1 Elderly market segment	24
4.1.3.2 CAREPATH related state of technology and development.....	25
4.1.3.3 Opportunities and barriers to introducing CAREPATH-like solution in health care	27
4.1.4 Germany	27
4.1.4.1 Elderly market segment	27
4.1.4.2 CAREPATH related state of technology and development.....	28
4.1.4.3 Opportunities and barriers to introducing CAREPATH-like solution in health care	28
4.1.5 Romania.....	29
4.1.5.1 Elderly market segment	29
4.1.5.2 CAREPATH related state of technology and development.....	29
4.1.5.3 Opportunities and barriers to introducing CAREPATH-like solution in health care	29
4.1.6 Turkey	30
4.1.6.1 Elderly market segment	30
4.1.6.2 CAREPATH related state of technology and development.....	30
4.1.6.3 Opportunities and barriers to introducing CAREPATH-like solution in health care	33
4.2 EXISTING SOLUTIONS IN PARTNER COUNTRIES	34
4.2.1 Switzerland	34
4.2.2 Germany	34
4.2.3 United Kingdom	35

**THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL
DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT.
THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.**

4.2.4	<i>Spain</i>	35
4.2.5	<i>Romania</i>	35
4.2.6	<i>Turkey</i>	36
5.	EXPLOITATION STRATEGY	37
5.1	CAREPATH EXPLOITABLE ASSETS.....	37
5.1.1	<i>Main Assets</i>	38
5.1.2	<i>Basic Assets</i>	39
5.1.2.1	BA1: Adaptive Integrated Care Platform	39
5.1.2.2	BA2: Patient Empowerment Platform	40
5.1.2.3	BA3: Health status and behavioural monitoring platform & Smart Early Warning System	40
5.1.2.4	BA4: Clinical Decision Support Module (CDSM) – Polypharmacy & Drug-Drug-Interaction	40
5.1.2.5	BA5: Clinical Decision Support Services for Automating Clinical Guidelines.....	41
5.1.2.6	BA6: CAREPATH Interoperability Middleware.....	41
5.2	COMPETITOR ANALYSIS	42
5.2.1	<i>CAREPATH MAs competitors</i>	42
5.2.2	<i>CAREPATH BAs competitors</i>	42
5.2.3	<i>Why existing market solutions do not offer full answer to the typical problems?</i>	46
5.3	CONSORTIUM PARTNERS' EXPLOITATION INTERESTS	48
5.4	INTELLECTUAL PROPERTY RIGHTS (IPR).....	49
5.5	BUSINESS MODEL AND VALUE PROPOSITION CANVAS	49
5.5.1	<i>Business model canvas</i>	49
5.5.2	<i>Value propositions</i>	52
5.5.2.1	Value proposition canvas for formal care givers	52
5.5.2.2	Value proposition canvas for multimorbid patients with dementia and informal caregivers	53
5.5.3	<i>CAREPATH SWOT analysis</i>	54
6.	ROUTE TO MARKET	55
6.1	EFFICIENT DISSEMINATION AND COMMUNICATION PLAN.....	55
6.2	FUTURE CERTIFICATION OF CAREPATH SOLUTION AS A MEDICAL DEVICE IN EU	55
6.2.1	<i>Description of the process to go through</i>	55
6.2.1.1	Steps	55
6.2.2	<i>Time Schedule</i>	56
6.2.3	<i>Readiness of documentations</i>	56
6.3	MEDICAL DEVICE REGULATION (MDR) COMPLIANCES TO BE FULFILLED.....	57
6.4	INITIAL ALLIANCES FOR THE COMMERCIALISATION OF THE MDR COMPLIANT SOLUTION.....	57
7.	CONCLUSIONS	58
8.	REFERENCES	59
9.	REVIEW STATUS	60
10.	DOCUMENT HISTORY	61